Newsroom
307 articles
FeaturedAs of 16th of May 2025 Guselkumab (Tremfya) has been approved for the treatment of Crohn’s disease & Ulcerative colitis. However, it was initially used for the treatment…
FeaturedWith the rising risk of antibiotics resistance, EMA’s human medicines committee (CHMP) has decided on readjusting the use of some antibiotics like azithromycin and limiting its indications, in…
FeaturedWith the AI being integrated in almost everything nowadays, FDA has decided to dive in and also integrate AI in their practice. AI has proven to be an…
FeaturedEMA’s safety committee, Pharmacovigilance Risk Assessment Committee (PRAC) recent review revealed negative mental health impact of finasteride and dutasteride on patients taking it for anti-hair loss purposes. Finasteride…
FeaturedAs part of global efforts to protect the environment, the Medicines and Healthcare products Regulatory Agency (MHRA) is playing a role by supporting changes to inhalers used by…
FeaturedThe FDA has just recently approved a new blood test called The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, that helps with the early detection of Alzheimer’s diseases in…
FeaturedWith Kaftrio being used for treatment of patients with Cystic Fibrosis, comes serious negative impact on patient’s psychological state. As of 25 February 2025, the MHRA received 300…
FeaturedThe UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for obecabtagene autoleucel (Aucatzyl)—a CAR T-cell therapy—for the treatment of adult patients with relapsed or…
FeaturedThe U.S. Food and Drug Administration (FDA) has taken the initiative to stop the use of concentrated ingestible fluoride present in prescription drugs of children. Toddlers or infants…
FeaturedAs of 30 April 2025, a new formulation for Nivolumab has been approved by The Medicines and Healthcare products Regulatory Agency (MHRA) making the treatment process much simpler…
FeaturedThe UK’s Medicines & Healthcare Products Regulatory agency has approved Acoramidis (Beyonttra) for the treatment of adult patients with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM), including both wild-type…
FeaturedAsthma Patients who rely solely on their blue inhalers may be putting their health at greater risk. That’s why The Medicines and Healthcare products Regulatory Agency (MHRA) is…
FeaturedThe UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Omaveloxolone (Skyclarys) as the first-ever treatment for Friedreich’s ataxia in patients aged 16 and older, a major…
FeaturedFor years now Thyroid Eye Disease (TED) has been a struggle to anyone suffering from it, with limited treatment options available on hand & sometimes the need to…
FeaturedEMA’s continuous straining efforts to develop & improve biosimilar medicine has been ongoing for decades now. While still maintaining the strict European Union safety standards with the aim…
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP
Request Consultation
Submit RFI/RFP